menu
    • menu
    [{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase II","graph3":"Zeria Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zeria Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zeria Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ITALY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ CSL Vifor"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Syneos Health"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Undisclosed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Relypsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Relypsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relypsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Relypsa \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Duke University \/ CSL Vifor","highestDevelopmentStatusID":"11","companyTruncated":"Duke University \/ CSL Vifor"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Relypsa","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Relypsa","highestDevelopmentStatusID":"11","companyTruncated":"Baylor College of Medicine \/ Relypsa"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Comprehensive Research Associates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase IV","graph3":"Comprehensive Research Associates","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Comprehensive Research Associates \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Comprehensive Research Associates \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Patiromer

    Menu

    Patiromer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University Medical Center Groningen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Medical Center Groningen

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Potassium Correction for RAAS Optimization in Chronic Kidney Disease

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 13, 2024

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Amsterdam University Medical Center | Frisius Medisch Centrum | Isala | CSL Vifor | Dutch Kidney Foundation | Health Holland

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mario Negri Institute for Pharmacological Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Mario Negri Institute for Pharmacological Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patiromer Trial in CKD Stage IIIB to V

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 27, 2023

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 13, 2023

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Tigermed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            November 29, 2021

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Tigermed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Comprehensive Research Associates

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Comprehensive Research Associates

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Hear...

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 25, 2019

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zeria Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zeria Pharmaceutical

                            Japan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Study of ZG-801 for the Treatment of Hyperkalemia

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 10, 2019

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 19, 2018

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NYU Langone Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NYU Langone Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 12, 2017

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hy...

                            Details : Patiromer is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperkalemia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 22, 2017

                            Lead Product(s) : Patiromer

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth